You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 129 No. 11, November 1994 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Papers
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (45)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Interleukin-6 Potentiates Neutrophil Priming With Platelet-Activating Factor

Walter L. Biffl, MD; Ernest E. Moore, MD; Frederick A. Moore, MD; Virginia S. Carl, MS; Fernando J. Kim, MD; Reginald J. Franciose, MD

Arch Surg. 1994;129(11):1131-1136.


Abstract



Background
Polymorphonuclear neutrophil (PMN) priming appears to be an important event in the pathogenesis of hyperinflammatory states, resulting in adult respiratory distress syndrome or multiple organ failure. Interleukin-6 (IL-6) is an integral mediator of the acute stress response to injury and infection, but excessive and prolonged systemic levels have been associated with morbidity and mortality following trauma, burns, and elective surgery. We hypothesized that IL-6 primed PMNs for exaggerated cytotoxicity. However, we have been unable to directly prime PMNs for superoxide release with IL-6.

Objective
To determine whether IL-6 acted in concert with another inflammatory mediator (platelet-activating factor [PAF]) to prime PMNs.

Methods
Polymorphonuclear neutrophils isolated from healthy human donors were incubated for varying times with IL-6 (0.01 to 100 ng/mL), PAF (0.01 to 100 ng/mL), or a combination of IL-6 and PAF. Superoxide production was then measured with and without the addition of the PMN-activating formylpeptide formylmethionyleucylphenylalanine.

Results
Over the range of times (5 to 90 minutes) and doses tested, IL-6 did not prime PMNs, while PAF primed PMNs in a dose- and time-dependent manner. Interleukin 6 (10 ng/mL) combined with a nonpriming concentration of PAF (0.1 ng/mL) primed PMNs for superoxide production over a range of incubation times.

Conclusion
The inflammatory mediators IL-6 and PAF act synergistically to prime PMNs in vitro. This observation may begin to elucidate the mechanistic role of IL-6 in pathologic clinical states.

(Arch Surg. 1994;129:1131-1136)



Author Affiliations



From the Department of Surgery, Denver General Hospital, University of Colorado Health Sciences Center.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Regulation of the Inflammatory Response: Enhancing Neutrophil Infiltration under Chronic Inflammatory Conditions
Bian et al.
J. Immunol. 2012;188:844-853.
ABSTRACT | FULL TEXT  

Analytic Review: Interleukin-6 in Surgery, Trauma, and Critical Care: Part I: Basic Science
Jawa et al.
J Intensive Care Med 2011;26:3-12.
ABSTRACT  

Prestorage Leukoreduction Prevents Accumulation of Matrix Metalloproteinase 9 in Stored Blood
Frake et al.
Arch Surg 2006;141:396-400.
ABSTRACT | FULL TEXT  

PAF receptor antagonist modulates neutrophil responses with thermal injury in vivo
Fazal et al.
Am. J. Physiol. Cell Physiol. 2001;281:C1310-C1317.
ABSTRACT | FULL TEXT  

Interleukin-6 Delays Neutrophil Apoptosis
Biffl et al.
Arch Surg 1996;131:24-30.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.